Clinical trials: Uremic Toxin
Hemolytic-Uremic Syndrome
Efficacy of INM004 in Children With STEC-HUS
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
- Trial name
- NCT06389474
- Testing
- INM004
- Where
- 52 sites in Argentina, Belgium and 7 more
- Volunteers
- 220 people
- Sponsor
- Inmunova S.A.
Bloody Diarrhea, STEC, Unspecified
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
The investigational medicinal product (IMP), INM004, proposes to neutralize the toxin in the bloodstream to prevent the interaction of the Stx with the specific receptor, by means of a polyclonal antibody to be administered upon…
- Conditions
- Bloody Diarrhea, STEC, Unspecified, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease
- Trial name
- NCT04132375
- Testing
- INM004
- Where
- 7 sites in Argentina
- Volunteers
- 11 people
- Sponsor
- Inmunova S.A.
Shiga-like Toxin-producing Escherichia Coli
Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.
- Trial name
- STEC-HUS (NCT01410916)
- Testing
- Eculizumab (Soliris®)
- Where
- 22 sites in Germany
- Volunteers
- 198 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hemolytic Uremic Syndrome of Childhood
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still no efficient specific therapy in that potentially devastating…
- Trial name
- ECULISHU (NCT02205541)
- Testing
- Eculizumab
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Hemolytic Uremic Syndrome (HUS) is a foodborne disease which mainly affects children. It is caused by Escherichia coli bacteria, which release a toxin called Shiga toxin within the body.
- Conditions
- Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease, Hemolytic-Uremic Syndrome
- Trial name
- NCT05569746
- Testing
- INM004, SoC
- Where
- 16 sites in Argentina
- Volunteers
- 57 people
- Sponsor
- Inmunova S.A.
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E.
- Trial name
- HIKO-STEC (NCT05219110)
- Testing
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Where
- 26 sites in United States, Canada
- Volunteers
- 1,040 people
- Sponsor
- University of Calgary
End Stage Renal Disease (ESRD), Kidney Failure, Chronic
Probiotic and Synbiotic Supplements in Hemodialysis Patients
This single-center randomized controlled trial evaluated the effects of natural probiotic and synbiotic supplementation on clinical and biochemical characteristics in adults with end-stage renal disease receiving maintenance…
- Conditions
- End Stage Renal Disease (ESRD), Kidney Failure, Chronic, Hemodialysis
- Trial name
- NCT07531186
- Testing
- Natural Probiotic Supplement, Natural Synbiotic Supplement (Probiotic + Prebiotic Oat Fiber)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Hemolytic-Uremic Syndrome
Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion
This study will provide feasibility data regarding the conduct of a clinical trail evaluating the use of early aggressive inpatient intravenous rehydration in children with Shiga Toxin producing E. coli infection.
- Trial name
- NCT03275792
- Testing
- D5-0.9%NS, Routine home oral rehydration
- Where
- Canada
- Sponsor
- University of Calgary
Hemolytic-uremic Syndrome, Escherichia Coli Infections
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype.
- Trial name
- SHU O104 CUB (NCT01406288)
- Testing
- HUS standard coverage care (including in ICU)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Bordeaux